Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint

Thrombosis and Haemostasis

Volumn 86, Issue 4, 2001, Pages 1126-1127

  Saxon, B R ^a   Shanks, D ^a   Jory, C B ^a   Williams, V ^a  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANKLE EDEMA; BOY; CASE REPORT; CLINICAL PROTOCOL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; HEMARTHROSIS; HEMOPHILIA A; HUMAN; IMMOBILIZATION; IMMUNOLOGICAL TOLERANCE; JOINT CHARACTERISTICS AND FUNCTIONS; JOINT EFFUSION; LETTER; MALE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; REST; SCHOOL CHILD; SPLINTING; SYNOVECTOMY; SYNOVIUM; TREATMENT OUTCOME; WHEELCHAIR;

EID: 0034758420     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616550     Document Type: Letter

References (5)

1. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
2. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
3. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
4. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
5. Prophylaxis in haemophilia: A double-blind controlled trial